PRME PRIME MEDICINE INC revenue, earnings and financials
For the quarter ended June 30, 2026, PRIME MEDICINE INC reported revenue of n/a, net income of −$42.1M and diluted EPS of −$0.24; for the fiscal year ended December 2025 revenue was $4.63M, up 55.3% on the year before.
PRME annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $4.63M, gross profit n/a, operating income −$208M, net income −$201M (margin -4342.4%), EPS −$1.35
- Fiscal year ended Dec 2024: revenue $2.98M, gross profit n/a, operating income −$202M, net income −$196M (margin -6566.6%), EPS −$1.65
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$205M, net income −$198M (margin n/a), EPS −$2.18
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$117M, net income −$122M (margin n/a), EPS −$4.19
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$84.5M, net income −$165M (margin n/a), EPS −$14.19
PRME quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$42.1M, EPS −$0.24
- Quarter ended Mar 31, 2026: revenue n/a, net income −$49.1M, EPS −$0.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue $838K (down 61.6% year over year), net income −$46.1M, EPS −$0.22
- Quarter ended Sep 30, 2025: revenue $1.23M (up 486.1% year over year), net income −$50.6M, EPS −$0.32
- Quarter ended Jun 30, 2025: revenue $1.12M, net income −$52.6M, EPS −$0.41
- Quarter ended Mar 31, 2025: revenue $1.45M (up 146.0% year over year), net income −$51.9M, EPS −$0.40
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.18M, net income −$42.3M, EPS −$0.31
- Quarter ended Sep 30, 2024: revenue $209K, net income −$52.5M, EPS −$0.44
- Quarter ended Jun 30, 2024: revenue $0, net income −$55.3M, EPS −$0.46
- Quarter ended Mar 31, 2024: revenue $591K, net income −$45.8M, EPS −$0.44
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$65.6M, EPS −$0.72
- Quarter ended Sep 30, 2023: revenue $0, net income −$50.7M, EPS −$0.55
- Quarter ended Jun 30, 2023: revenue $0, net income −$42.4M, EPS −$0.47
- Quarter ended Mar 31, 2023: revenue $0, net income −$39.4M, EPS −$0.44
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$39.3M, EPS $0.76
- Quarter ended Sep 30, 2022: revenue n/a, net income −$29.4M, EPS −$1.61
- Quarter ended Jun 30, 2022: revenue n/a, net income −$29.3M, EPS −$1.76
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.8M, EPS −$1.58
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$62.9M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$16.4M, EPS −$1.52
PRME cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$163M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$123M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$165M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$132M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$34.1M, share buybacks n/a
PRME balance sheet
- Jun 30, 2026: cash $47.5M, total assets $249M, total liabilities $209M, shareholders' equity $39.8M
- Mar 31, 2026: cash $64.1M, total assets $295M, total liabilities $218M, shareholders' equity $76.7M
- Dec 31, 2025: cash $63.0M, total assets $343M, total liabilities $222M, shareholders' equity $121M
- Sep 30, 2025: cash $71.4M, total assets $385M, total liabilities $223M, shareholders' equity $162M
- Jun 30, 2025: cash $53.8M, total assets $279M, total liabilities $218M, shareholders' equity $60.9M
- Mar 31, 2025: cash $91.9M, total assets $328M, total liabilities $221M, shareholders' equity $107M
- Dec 31, 2024: cash $182M, total assets $298M, total liabilities $144M, shareholders' equity $153M
- Sep 30, 2024: cash $118M, total assets $333M, total liabilities $143M, shareholders' equity $190M
What is PRME's revenue?
PRIME MEDICINE INC reported $4.63M of revenue for the fiscal year ended December 2025.
Is PRME profitable?
No. PRIME MEDICINE INC lost $188M over the last four quarters.
What is PRME's EPS?
Diluted earnings per share over the last four quarters were −$1.06; −$0.24 in the latest quarter.